Literature DB >> 7827757

Ultrastructural studies of bones from patients with osteogenesis imperfecta.

W Traub1, T Arad, U Vetter, S Weiner.   

Abstract

Bone samples from patients suffering from osteogenesis imperfecta (OI) types I, II, III and IV, as well as normal controls, were studied by scanning (SEM) and transmission electron microscopy (TEM). SEM views of normal bone at low magnification show coherent structure, with regular striations due to a lamellar plywood-like arrangement of the mineralized collagen fibrils. Compact lamellar bone was also found in various OI specimens, but in limited disconnected regions separated by open spaces. Furthermore, some OI, but not normal, bones have regions of loose unconnected fibers and others of apparently abnormally dense mineral deposition. High resolution TEM studies of OI bone fragments have served to elucidate the structures of these different textures. There appears to be a substantial, though reduced, proportion of normal lamellar bone even in quite severe OI. However, the regions of loose fibers are largely unmineralized and probably contain abnormal collagen. Other regions are overmineralized, with generally small unorganized apatite crystals deposited onto fibril surfaces or in separate clusters. These structural abnormalities, together with the paucity of normal bone, may explain the fragility of OI bones.

Entities:  

Mesh:

Year:  1994        PMID: 7827757     DOI: 10.1016/0945-053x(94)90200-3

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  15 in total

Review 1.  The role of collagen in bone strength.

Authors:  S Viguet-Carrin; P Garnero; P D Delmas
Journal:  Osteoporos Int       Date:  2005-12-09       Impact factor: 4.507

2.  Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress.

Authors:  K Misof; W J Landis; K Klaushofer; P Fratzl
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

Authors:  W G Cole; D Chan; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1996-11       Impact factor: 6.318

Review 4.  Bone mineralization: from tissue to crystal in normal and pathological contexts.

Authors:  Y Bala; D Farlay; G Boivin
Journal:  Osteoporos Int       Date:  2012-12-11       Impact factor: 4.507

5.  A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases.

Authors:  J M Pace; D Chitayat; M Atkinson; W R Wilcox; U Schwarze; P H Byers
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

6.  Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta.

Authors:  Carolyne Albert; John Jameson; Peter Smith; Gerald Harris
Journal:  Bone       Date:  2014-06-11       Impact factor: 4.398

Review 7.  Biominerals--hierarchical nanocomposites: the example of bone.

Authors:  Elia Beniash
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011 Jan-Feb

8.  How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone.

Authors:  R O Ritchie; S J Shefelbine; A Carriero; E A Zimmermann; A Paluszny; S Y Tang; H Bale; B Busse; T Alliston; G Kazakia
Journal:  J Bone Miner Res       Date:  2014-06       Impact factor: 6.741

9.  CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII.

Authors:  N Fratzl-Zelman; R Morello; B Lee; F Rauch; F H Glorieux; B M Misof; K Klaushofer; P Roschger
Journal:  Bone       Date:  2009-11-04       Impact factor: 4.398

10.  Bone mineralization in an osteogenesis imperfecta mouse model studied by small-angle x-ray scattering.

Authors:  P Fratzl; O Paris; K Klaushofer; W J Landis
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.